Balidis Miltiadis, Mikropoulos Dimitrios, Gatzioufas Zisis, de Politis Penelope B, Sidiropoulos Georgios, Vassiliadis Vassilios
98022Ophthalmica Eye Institute, Thessaloniki, Greece.
Department of Ophthalmology, Faculty of Medicine, 388413Aristotle University of Thessaloniki (AUTH), Thessaloniki, Greece.
Eur J Ophthalmol. 2021 Nov 26:11206721211064033. doi: 10.1177/11206721211064033.
This study intends to add to previous reports on acute corneal graft rejection following anti-severe acute respiratory syndrome-coronavirus-2 vaccination, providing data to corroborate a possible causative relationship between anti-COVID-19 immunization and corneal graft rejection, regardless of vaccine or graft type.
This report describes 4 cases of acute-onset rejection as early as 5 days following the first dose of anti-severe acute respiratory syndrome-coronavirus-2 vaccine types not yet referred for corneal allograft. Patients were individually given the Moderna messenger RNA-1273 COVID-19 vaccine (2 patients) and the AstraZeneca COVID-19 vaccine, Vaxzevria, AZD1222 (2 patients).
Even though a direct causative effect is hard to prove, temporal proximity between anti-severe acute respiratory syndrome-coronavirus-2 vaccines of different types and consecutive reports of corneal graft rejection indicates the need for further investigation. Consistent advice must be given to corneal transplant patients regarding such risk.
本研究旨在补充先前关于抗严重急性呼吸综合征冠状病毒2疫苗接种后急性角膜移植排斥反应的报告，提供数据以证实抗2019冠状病毒病免疫接种与角膜移植排斥反应之间可能存在的因果关系，无论疫苗或移植类型如何。
本报告描述了4例急性起病的排斥反应病例，最早在接种第一剂抗严重急性呼吸综合征冠状病毒2疫苗后5天出现，这些疫苗类型尚未用于角膜同种异体移植。患者分别接种了莫德纳信使核糖核酸-1273 2019冠状病毒病疫苗（2例患者）和阿斯利康2019冠状病毒病疫苗Vaxzevria、AZD1222（2例患者）。
尽管很难证明存在直接因果效应，但不同类型的抗严重急性呼吸综合征冠状病毒2疫苗与角膜移植排斥反应的连续报告之间在时间上的接近表明需要进一步研究。必须就此类风险向角膜移植患者提供一致的建议。
